Companion diagnostics at the intersection of personalized medicine and healthcare delivery.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Metabolomics of infectious diseases in the era of personalized medicine.Frontiers in molecular biosciences · 2023
   Review
2. Longevity leap: mind the healthspan gap.NPJ Regenerative medicine · 2021
   Review
3. Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to ImproveWorld journal of oncology · 2021
   Review
4. Regenerative medicine clinical readiness.Regenerative medicine · 2021
   Review
5. Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery.The pharmacogenomics journal · 2020
   Review
6. Clinical Pharmacology & Therapeutics: Past, Present, and Future.Clinical pharmacology and therapeutics · 2017
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as